Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. - Wikidata - awgldk - TriplyDB

Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.

Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.

http://www.wikidata.org/entity/Q43433524

about

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Safety concerns about intravenous iron therapy in patients with chronic kidney disease Considerations and challenges in defining optimal iron utilization in hemodialysis Plasma vitamin C levels in ESRD patients and occurrence of hypochromic erythrocytes.Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response.The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients.Intravenous iron exposure and mortality in patients on hemodialysis TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients Iron supplementation and mortality in incident dialysis patients: an observational study.Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis.Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.Iron dosing in kidney disease: inconsistency of evidence and clinical practice.Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study.The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease.Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death.Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients.Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.Anaemia management and mortality risk in chronic kidney disease.Therapy of anemia: is it only a number to reach or are there other variables to control?How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis.Iron toxicity: relevance for dialysis patients.Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.The Labile Side of Iron Supplementation in CKD Management of the Dialysis Patient with Sickle Cell Disease.Novel iron-containing phosphate binders for treatment of hyperphosphatemia.Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD.Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution.Diagnosing and preventing iron overload.Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.Small bowel pigmentation.Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.Iron Overload in Dialysis Patients: Rust or Bust?Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis.

P2860

Q26752664-AA0F1C10-3D68-4B64-AD10-31A3B03816A4 Q26764881-DFDDB99C-653C-447C-B5DF-5D7224D9A480 Q28088564-B1011641-BE8E-4CF7-8116-E24238A9D262 Q30313877-F7251D62-7ABE-4AFF-8BCC-77FB609B95B6 Q30418035-67F14CCC-9D09-461E-9D6F-4FEB1B6897A3 Q33832885-B939A34C-ACBF-41BE-9828-AF1FA814B82B Q34455198-10274826-E7AF-423D-9F5C-46A030403F97 Q34513137-5FB8A5B8-9962-4013-A1E4-A35D5CF3DE58 Q34612274-5C08F763-D727-4E24-8FD0-DF99EFD4BBAD Q34704499-751C8732-2956-4C7E-9546-F63F80F1DED6 Q34884492-2611A9D7-3257-497A-A05F-5CF37BD6C4B1 Q35022235-E93E9C16-6EE1-4838-88D4-E6A6FBCBAA91 Q35474305-03B7A018-8C9B-4708-B4EF-FA98120462B4 Q35693595-ED21D05F-B144-4F58-A281-7DE17B581144 Q36133152-BA9E675D-8448-4D81-A237-E1F3C42E204B Q36300989-4B7D467F-75EB-436C-B765-BB12ADEFD26C Q36315311-0223D80D-7C40-4CA2-AC0B-0D3849CD93C3 Q36471843-79946D6D-1A9D-45B4-A2CC-26119B171777 Q36830103-25C76AAD-15D0-4EBB-9003-6E8F63534164 Q37369071-30ECC08E-A951-456E-A646-A3D4268F8CE1 Q37570855-BBF3D57C-F1F0-4310-AB59-E6EE1D8460C8 Q37701899-57B18885-BB07-40B3-8438-CC98CF98FED8 Q38084470-B05C30D3-663F-47D3-8EC5-39EAE98875F2 Q38111881-32537F9E-2AB3-47BF-8646-7092FAAD856B Q38114158-F389A92B-BFA5-4889-A36C-B584AC59E14A Q38156094-91480861-538E-43E0-A579-771D41D903AF Q38229636-16752784-22EF-4E11-A82D-3E699DDDABCC Q38496987-C5B4661F-971A-437A-A043-F5C7C32F35F8 Q38547177-049F2F7C-3288-49F2-8165-7E16B575FB9E Q38570622-17D45134-4F55-43CE-98B6-EAF0485ABCF0 Q38741680-2FA05E34-C79A-4E83-AD76-841506D01E26 Q38884441-E4762B53-2A30-41E8-96FD-AA443960DC82 Q39192941-40960211-E8CC-4BD8-9609-8B126C790775 Q39216391-DEBA37A7-7A9B-44DF-A919-B808A70BA426 Q42364904-5BB691AC-DD73-4021-9172-586E521B293E Q43236775-C0BB6E7A-40E7-4197-B14C-D1282E11F8FF Q44676908-54E9389B-E09B-40BD-9597-3410D5F1CAA4 Q45012876-30CF3C50-04F1-4976-A1A9-B38A83C3D161 Q47093609-DC060FFE-D687-45C5-BE2C-09ABF74058EA Q47102467-EB7D4440-7356-4C95-8DB9-CEFC99DC5385

P2860

Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.

http://www.wikidata.org/entity/Q43433524

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@en

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@nl

type

label

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@en

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@nl

prefLabel

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@en

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@nl

P1433

Q43433524-FF54DBEC-75B0-447D-B7EA-4161F7CE0E11

P1476

Q43433524-9E4542D0-5CEE-494E-9A7E-5A3BE62E46D8

P2093

Q43433524-3CAC2B19-A899-45D0-8176-7B4035C07C86

Q43433524-55AF2F9F-A31D-4D29-9A9E-A7235ED513DB

Q43433524-5C1BFD77-FA3A-44A3-9E07-A88F591B0FFB

Q43433524-6E461CC0-626C-4D5E-B102-FFB0D5AAB58A

Q43433524-87CC0E76-74E8-419D-8EEE-21E4CE727D6B

Q43433524-88A9DA5D-5B1D-4D78-9BA6-94A06B130D42

Q43433524-95DB164C-4766-46AB-98C3-2DB6D8D9286E

Q43433524-B55C3047-71A8-4AEA-B3F1-9DC2071F342A

Q43433524-B741F64B-6812-4D6E-AA24-49ECFBA4E192

Q43433524-D5E75BF1-FD9E-4661-8AD2-1376B9EEAE31

P304

Q43433524-4F6DB65B-AED5-4892-B86B-B2AFB83F5B26

P31

Q43433524-28E22189-8E30-4097-9B13-2061907BDB74

P356

Q43433524-F24123F3-EF6F-4387-AD01-493A4C391437

P407

Q43433524-AEA1B272-ADB9-49C8-8D60-BF42E283AA96

P433

Q43433524-189377D2-2977-4AFB-88BC-2A74213BD695

P478

Q43433524-00A326E2-3B74-430B-AB7A-8DF89115944A

P577

Q43433524-04539858-FBE4-4562-A8BF-82F955E849F5

P5875

Q43433524-FE9DE6AF-0145-4995-A6F0-66722BA63CB5

P698

Q43433524-3286F335-1D5A-4B0D-8B72-4629A0A29443

P356

J.AMJMED.2012.01.015

P1433

The American Journal of Medicine

P1476

Hemodialysis-associated hemosi ...... imulating agents: a MRI study.

@en

P2093

Abbes Benmaadi

http://www.w3.org/2001/XMLSchema#string

Catherine Bounhiol

http://www.w3.org/2001/XMLSchema#string

Christelle Loridon

http://www.w3.org/2001/XMLSchema#string

Gabrielle Machado

http://www.w3.org/2001/XMLSchema#string

Gilles Drahi

http://www.w3.org/2001/XMLSchema#string

Guy Rostoker

http://www.w3.org/2001/XMLSchema#string

Hervé Dahan

http://www.w3.org/2001/XMLSchema#string

Mireille Griuncelli

http://www.w3.org/2001/XMLSchema#string

Myriam Roy

http://www.w3.org/2001/XMLSchema#string

Phillippe Janklewicz

http://www.w3.org/2001/XMLSchema#string

P304

991-999.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJMED.2012.01.015

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236863039

http://www.w3.org/2001/XMLSchema#string

P698

22998881

http://www.w3.org/2001/XMLSchema#string